104 related articles for article (PubMed ID: 38773728)
1. Coexistence of MYCN-activating mutation and amplification in a patient with neuroblastoma.
Kojima M; Touge R; Kurihara S; Saeki I; Takahashi S; Hiyama E
Pediatr Blood Cancer; 2024 May; ():e31115. PubMed ID: 38773728
[No Abstract] [Full Text] [Related]
2. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
[TBL] [Abstract][Full Text] [Related]
3. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
[TBL] [Abstract][Full Text] [Related]
4. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
[TBL] [Abstract][Full Text] [Related]
5. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
6. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
7. Image-defined risk factors associated with MYCN oncogene amplification in neuroblastoma and their association with overall survival.
Wang H; Li T; Ni X; Chen X; He L; Cai J
Abdom Radiol (NY); 2024 Mar; ():. PubMed ID: 38436700
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
Bhardwaj N; Das G; Srinivasan R
J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.
Boboila S; Lopez G; Yu J; Banerjee D; Kadenhe-Chiweshe A; Connolly EP; Kandel JJ; Rajbhandari P; Silva JM; Califano A; Yamashiro DJ
Oncogene; 2018 Oct; 37(40):5451-5465. PubMed ID: 29880876
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299
[TBL] [Abstract][Full Text] [Related]
11. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
12. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
14. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
15. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
16. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
17. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
18. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
20. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]